|
WO2020254266A1
|
|
Method for determining the risk of a thromboembolic event
|
|
WO2020193758A1
|
|
Combination therapy of alk-positive neoplasia
|
|
WO2020078894A1
|
|
Oncotherapeutic combinations
|
|
EP3800245A1
|
|
Embryo transfer medium
|
|
EP3748017A1
|
|
Methylation markers for predicting sensitivity to treatment with antibody based therapy
|
|
AU2019229090A1
|
|
Fecal matter for prevention or treatment of autoimmune diseases
|
|
NL2022406B1
|
|
Ventilation Perfusion Protector
|
|
WO2019042950A1
|
|
Improved hiv envelope glycoprotein immunogens
|
|
NL2021365B1
|
|
Fecal matter for prevention or treatment of autoimmune diseases
|
|
WO2018193129A1
|
|
Inhibitors of bmp2 and bmp4 signalling for use in the treatment of barrett's esophagus
|
|
EP3593143A1
|
|
A screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios
|
|
WO2018146162A1
|
|
Molecular biomarker for prognosis of sepsis patients
|
|
WO2018041726A1
|
|
Biomarkers for determining the presence of an unstable atherosclerotic plaque
|
|
US2019249256A1
|
|
Method for determining the risk of developing arthritis
|
|
WO2018002378A1
|
|
Hepatic cell line resistant to dimethyl sulfoxide, cell culture and uses thereof
|
|
NL2019089B1
|
|
Polarization microscope
|
|
WO2017076974A1
|
|
Biomarker for risk stratification in cardiovascular disease
|
|
WO2017072360A1
|
|
Flow cytometry method for determination of size and refractive index of substantially spherical single particles
|
|
WO2017068198A1
|
|
Biomarker for predicting coronary artery disease in smokers
|
|
WO2017055522A1
|
|
Stabilized env proteins of hiv
|
